Chimeric Polioviruses That Include Sequences Derived from Two Independent Antigenic Sites of Foot-and-mouth Disease Virus (FMDV) Induce Neutralizing Antibodies Against FMDV in Guinea Pigs

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1991 Jun 1

PMID 1709696

Citations 16

Authors

J D Kitson

K L Burke

L A Pullen

G J Belsham

J W Almond

Affiliations

Soon will be listed here.

Abstract

Five poliovirus recombinants containing sequences corresponding to foot-and-mouth disease virus (FMDV) antigenic sites were constructed. Viable virus was recovered from four of these plasmids, in which the VP1 beta B-beta C loop (antigenic site 1) of poliovirus type 1 Sabin had been replaced with sequences derived from the VP1 beta G-beta H loop (antigenic site 1) of FMDV O1 Kaufbeuren (O1K), chimera O1.1 (residues 141 to 154), chimera O1.2 (residues 147 to 156), and chimera O1.3 (residues 140 to 160) or from the beta B-beta C loop of VP1 (antigenic site 3) in chimera O3.1 (residues 40 to 49). One chimera (O1.3) was neutralized by FMDV-specific polyclonal serum and monoclonal antibodies directed against antigenic site 1 of FMDV. Chimeras O1.3 and O3.1 induced site-specific FMDV-neutralizing antibodies in guinea pigs. Chimera O1.3 was capable of inducing a protective response against FMDV challenge in some guinea pigs.

Citing Articles

Structural prediction of chimeric immunogen candidates to elicit targeted antibodies against betacoronaviruses.

Simpson J, Kasson P PLoS Comput Biol. 2025; 21(2):e1012812.

PMID: 39908344 PMC: 11809852. DOI: 10.1371/journal.pcbi.1012812.

Serological Conversion through a Second Exposure to Inactivated Foot-and-Mouth Disease Virus Expressing the JC Epitope on the Viral Surface.

Hwang S, Shin S, Park S, Lee M, Kim S, Lee J Vaccines (Basel). 2023; 11(9).

PMID: 37766163 PMC: 10537882. DOI: 10.3390/vaccines11091487.

Structural prediction of chimeric immunogens to elicit targeted antibodies against betacoronaviruses.

Simpson J, Kasson P bioRxiv. 2023; .

PMID: 36778336 PMC: 9915606. DOI: 10.1101/2023.01.31.526494.

Challenges and prospects for the control of foot-and-mouth disease: an African perspective.

Maree F, Kasanga C, Scott K, Opperman P, Melanie C, Sangula A Vet Med (Auckl). 2020; 5:119-138.

PMID: 32670853 PMC: 7337166. DOI: 10.2147/VMRR.S62607.

Recombinant Encephalomyocarditis Viruses Elicit Neutralizing Antibodies against PRRSV and CSFV in Mice.

Zhu S, Guo X, Keyes L, Yang H, Ge X PLoS One. 2015; 10(6):e0129729.

PMID: 26076449 PMC: 4468123. DOI: 10.1371/journal.pone.0129729.

References

Parry N, Fox G, Rowlands D, Brown F, Fry E, Acharya R . Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature. 1990; 347(6293):569-72. DOI: 10.1038/347569a0. View

Minor P, Ferguson M, Phillips A, MAGRATH D, Huovilainen A, Hovi T . Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus. J Gen Virol. 1987; 68 ( Pt 7):1857-65. DOI: 10.1099/0022-1317-68-7-1857. View

Murray M, Kuhn R, Arita M, Kawamura N, Nomoto A, Wimmer E . Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proc Natl Acad Sci U S A. 1988; 85(9):3203-7. PMC: 280172. DOI: 10.1073/pnas.85.9.3203. View

Burke K, Dunn G, Ferguson M, Minor P, Almond J . Antigen chimaeras of poliovirus as potential new vaccines. Nature. 1988; 332(6159):81-2. DOI: 10.1038/332081a0. View

Fox G, Parry N, Barnett P, McGinn B, Rowlands D, Brown F . The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol. 1989; 70 ( Pt 3):625-37. DOI: 10.1099/0022-1317-70-3-625. View

van der Werf S, Bradley J, Wimmer E, Studier F, Dunn J . Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. Proc Natl Acad Sci U S A. 1986; 83(8):2330-4. PMC: 323290. DOI: 10.1073/pnas.83.8.2330. View

Earle J, Skuce R, Fleming C, Hoey E, Martin S . The complete nucleotide sequence of a bovine enterovirus. J Gen Virol. 1988; 69 ( Pt 2):253-63. DOI: 10.1099/0022-1317-69-2-253. View

Stave J, Card J, MORGAN D, Vakharia V . Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants. Virology. 1988; 162(1):21-9. DOI: 10.1016/0042-6822(88)90390-x. View

Pfaff E, Thiel H, Beck E, Strohmaier K, Schaller H . Analysis of neutralizing epitopes on foot-and-mouth disease virus. J Virol. 1988; 62(6):2033-40. PMC: 253288. DOI: 10.1128/JVI.62.6.2033-2040.1988. View

10.

Rossmann M, Arnold E, Erickson J, Frankenberger E, Griffith J, Hecht H . Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 1985; 317(6033):145-53. DOI: 10.1038/317145a0. View

11.

Hogle J, Chow M, Filman D . Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985; 229(4720):1358-65. DOI: 10.1126/science.2994218. View

12.

Mccullough K, Crowther J, Butcher R . Alteration in antibody reactivity with foot-and-mouth disease virus (FMDV) 146S antigen before and after binding to a solid phase or complexing with specific antibody. J Immunol Methods. 1985; 82(1):91-100. DOI: 10.1016/0022-1759(85)90228-5. View

13.

Murdin A, Wimmer E . Construction of a poliovirus type 1/type 2 antigenic hybrid by manipulation of neutralization antigenic site II. J Virol. 1989; 63(12):5251-7. PMC: 251190. DOI: 10.1128/JVI.63.12.5251-5257.1989. View

14.

Parry N, Ouldridge E, Barnett P, Clarke B, Francis M, Fox J . Serological prospects for peptide vaccines against foot-and-mouth disease virus. J Gen Virol. 1989; 70 ( Pt 11):2919-30. DOI: 10.1099/0022-1317-70-11-2919. View

15.

Burke K, Evans D, Jenkins O, Meredith J, DSouza E, Almond J . A cassette vector for the construction of antigen chimaeras of poliovirus. J Gen Virol. 1989; 70 ( Pt 9):2475-9. DOI: 10.1099/0022-1317-70-9-2475. View

16.

Wiegers K, Uhlig H, Dernick R . N-AgIB of poliovirus type 1: a discontinuous epitope formed by two loops of VP1 comprising residues 96-104 and 141-152. Virology. 1989; 170(2):583-6. DOI: 10.1016/0042-6822(89)90452-2. View

17.

Parry N, Barnett P, Ouldridge E, Rowlands D, Brown F . Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents. J Gen Virol. 1989; 70 ( Pt 6):1493-503. DOI: 10.1099/0022-1317-70-6-1493. View

18.

Barnett P, Ouldridge E, Rowlands D, Brown F, Parry N . Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. J Gen Virol. 1989; 70 ( Pt 6):1483-91. DOI: 10.1099/0022-1317-70-6-1483. View

19.

McCahon D, Crowther J, Belsham G, Kitson J, Duchesne M, Have P . Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. J Gen Virol. 1989; 70 ( Pt 3):639-45. DOI: 10.1099/0022-1317-70-3-639. View

20.

Baxt B, Vakharia V, Moore D, Franke A, MORGAN D . Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. J Virol. 1989; 63(5):2143-51. PMC: 250631. DOI: 10.1128/JVI.63.5.2143-2151.1989. View